Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Back to Agenda

Session 9 Track 3: Evolving Regulatory Landscape for Oligonucleotide Control Strategy and Comparability

Vice President, Analytical Development and Quality Control

Ionis Pharmaceuticals, Inc., United States

Session 9 Track 3: Evolving Regulatory Landscape for Oligonucleotide Control Strategy and Comparability

Have an account?